Discovery of carmegliptin: A potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
作者:Patrizio Mattei、Markus Boehringer、Patrick Di Giorgio、Holger Fischer、Michael Hennig、Joerg Huwyler、Buelent Koçer、Bernd Kuhn、Bernd M. Loeffler、Alexander MacDonald、Robert Narquizian、Etienne Rauber、Elena Sebokova、Urs Sprecher
DOI:10.1016/j.bmcl.2009.12.024
日期:2010.2
synthesis, and SAR are described for a class of DPP-IV inhibitors based on aminobenzo[a]quinolizines with non-aromatic substituents in the S1 specificity pocket. One representative thereof, carmegliptin (8p), was chosen for clinical development. Its X-ray structure in complex with the enzyme and early efficacy data in animal models of type 2 diabetes are also presented.
针对一类基于S1特异性口袋中具有非芳族取代基的氨基苯并[ a ]喹唑啉的DPP-IV抑制剂的设计,合成和SAR进行了描述。选择其代表卡格列汀(8p)进行临床开发。还介绍了其与酶复合的X射线结构以及2型糖尿病动物模型中的早期功效数据。